{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:32:15Z","timestamp":1772119935521,"version":"3.50.1"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,9,10]],"date-time":"2011-09-10T00:00:00Z","timestamp":1315612800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s11899-011-0099-5","type":"journal-article","created":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T08:43:28Z","timestamp":1315557808000},"page":"207-215","source":"Crossref","is-referenced-by-count":6,"title":["Rituximab Maintenance Versus Radioimmunotherapy Consolidation in Follicular Lymphoma: Which, When, and for Whom?"],"prefix":"10.1007","volume":"6","author":[{"given":"Roswitha","family":"Forstpointner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,9,10]]},"reference":[{"key":"99_CR1","first-page":"75","volume":"20","author":"SJ Horning","year":"1993","unstructured":"Horning SJ. Natural history of and therapy for the indolent non-Hodgkin\u2019s lymphomas. Semin Oncol. 1993;20:75\u201388.","journal-title":"Semin Oncol."},{"key":"99_CR2","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","volume":"99","author":"H Schulz","year":"2007","unstructured":"Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99:706\u201314.","journal-title":"J Natl Cancer Inst."},{"key":"99_CR3","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825\u201333.","journal-title":"J Clin Oncol."},{"key":"99_CR4","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","volume":"20","author":"JD Hainsworth","year":"2002","unstructured":"Hainsworth JD, Litchy S, Burris 3rd HA, et al. Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin\u2019s lymphoma. J Clin Oncol. 2002;20:4261\u20137.","journal-title":"J Clin Oncol."},{"key":"99_CR5","doi-asserted-by":"crossref","first-page":"486a","DOI":"10.1182\/blood.V108.11.486.486","volume":"108","author":"P Colombat","year":"2006","unstructured":"Colombat P, Brousse N, Morschhauser F, Franchi-Rezgui P. Single treatment with rituximab monotherapy for low-tumor burden follicular lymphoma (FL): survival analyses with extended Follow-Up (F\/Up) of 7\u00a0years. Blood. 2006;108:486a.","journal-title":"Blood"},{"key":"99_CR6","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1182\/blood-2003-10-3411","volume":"103","author":"M Ghielmini","year":"2004","unstructured":"Ghielmini M, Schmitz SF, Cogliatti SB, et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly \u00d7 4 schedule. Blood. 2004;103:4416\u201323.","journal-title":"Blood."},{"key":"99_CR7","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","volume":"28","author":"G Martinelli","year":"2010","unstructured":"\u2022 Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98. J Clin Oncol. 2010;28:4480\u20134. Long-term follow-up proves the extended duration of remission after rituximab monotherapy in a subset of patients.","journal-title":"J Clin Oncol."},{"key":"99_CR8","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064\u201371.","journal-title":"Blood."},{"key":"99_CR9","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1182\/blood-2005-01-0016","volume":"106","author":"W Hiddemann","year":"2005","unstructured":"Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725\u201332.","journal-title":"Blood."},{"key":"99_CR10","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood-2004-08-3175","volume":"105","author":"R Marcus","year":"2005","unstructured":"Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417\u201323.","journal-title":"Blood."},{"key":"99_CR11","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","volume":"25","author":"M Herold","year":"2007","unstructured":"Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986\u201392.","journal-title":"J Clin Oncol."},{"key":"99_CR12","doi-asserted-by":"crossref","unstructured":"Foussard C, Mounier N, Van Hoof A, et al. Update of the FL2000 randomized trial combining rituximab to CHVP-Interferon in follicular lymphoma (FL) patients [abstract 7508]. J Clin Oncol (Meeting Abstracts) 2006;24:abstract 7508.","DOI":"10.1200\/jco.2006.24.18_suppl.7508"},{"key":"99_CR13","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","volume":"108","author":"MH Oers van","year":"2006","unstructured":"van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295\u2013301.","journal-title":"Blood."},{"key":"99_CR14","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","volume":"18","author":"TA Davis","year":"2000","unstructured":"Davis TA, Grillo-Lopez AJ, White CA, et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment. J Clin Oncol. 2000;18:3135\u201343.","journal-title":"J Clin Oncol."},{"key":"99_CR15","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1023\/A:1008416911099","volume":"9","author":"NL Berinstein","year":"1998","unstructured":"Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin\u2019s lymphoma. Ann Oncol. 1998;9:995\u20131001.","journal-title":"Ann Oncol."},{"key":"99_CR16","first-page":"465","volume":"44","author":"GA Wiseman","year":"2003","unstructured":"Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin\u2019s lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465\u201374.","journal-title":"J Nucl Med."},{"key":"99_CR17","first-page":"21S","volume":"39","author":"RL Wahl","year":"1998","unstructured":"Wahl RL, Zasadny KR, MacFarlane D, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med. 1998;39:21S\u20137S.","journal-title":"J Nucl Med."},{"key":"99_CR18","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1200\/JCO.2004.00.9217","volume":"23","author":"RI Fisher","year":"2005","unstructured":"Fisher RI, Kaminski MS, Wahl RL, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin\u2019s lymphomas. J Clin Oncol. 2005;23:7565\u201373.","journal-title":"J Clin Oncol."},{"key":"99_CR19","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/cncr.22617","volume":"109","author":"TE Witzig","year":"2007","unstructured":"Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007;109:1804\u201310.","journal-title":"Cancer."},{"key":"99_CR20","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2005.12.171","volume":"23","author":"LN Gordan","year":"2005","unstructured":"Gordan LN, Grow WB, Pusateri A, Douglas V, Mendenhall NP, Lynch JW. Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. J Clin Oncol. 2005;23:1096\u2013102.","journal-title":"J Clin Oncol."},{"key":"99_CR21","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1182\/blood-2008-10-185280","volume":"113","author":"SP Hilchey","year":"2009","unstructured":"Hilchey SP, Hyrien O, Mosmann TR, et al. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a \u201cvaccinal effect\u201d of rituximab. Blood. 2009;113:3809\u201312.","journal-title":"Blood."},{"key":"99_CR22","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1093\/annonc\/mdi320","volume":"16","author":"M Ghielmini","year":"2005","unstructured":"Ghielmini M, Rufibach K, Salles G, et al. Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol. 2005;16:1675\u201382.","journal-title":"Ann Oncol."},{"key":"99_CR23","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1080\/10428190701704647","volume":"49","author":"E Kimby","year":"2008","unstructured":"Kimby E, Jurlander J, Geisler C, et al. Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: a randomized phase II study from the Nordic Lymphoma Group. Leuk Lymphoma. 2008;49:102\u201312.","journal-title":"Leuk Lymphoma."},{"key":"99_CR24","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1200\/JCO.2005.12.191","volume":"23","author":"JD Hainsworth","year":"2005","unstructured":"Hainsworth JD, Litchy S, Shaffer DW, Lackey VL, Grimaldi M, Greco FA. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin\u2019s lymphoma\u2013a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2005;23:1088\u201395.","journal-title":"J Clin Oncol."},{"key":"99_CR25","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1182\/blood-2006-04-016725","volume":"108","author":"R Forstpointner","year":"2006","unstructured":"Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood. 2006;108:4003\u20138.","journal-title":"Blood."},{"key":"99_CR26","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MH Oers van","year":"2010","unstructured":"\u2022 van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin\u2019s lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28:2853\u20138. This article reports on the long-term follow-up of a randomized study of 465 patients, which led to the approval of rituximab maintenance in relapsed FL.","journal-title":"J Clin Oncol."},{"key":"99_CR27","doi-asserted-by":"crossref","first-page":"2769a","DOI":"10.1182\/blood.V108.11.2769.2769","volume":"108","author":"M Dreyling","year":"2006","unstructured":"Dreyling M, Forstpointner R, Boeck H-P, et al. combined immuno-chemotherapy followed by rituximab maintenance is an effective salvage treatment after prior rituximab containing therapy: results of a GLSG-subgroup analysis in patients with relapsed indolent lymphoma [abstract]. Blood. 2006;108:2769a.","journal-title":"Blood."},{"key":"99_CR28","doi-asserted-by":"crossref","first-page":"8005","DOI":"10.1200\/jco.2010.28.15_suppl.8005","volume":"28","author":"R Pettengell","year":"2010","unstructured":"Pettengell R, Schmitz N, Gisselbrecht C, et al. Randomized study of rituximab in patients with relapsed or resistant follicular lymphoma prior to high-dose therapy as in vivo purging and to maintain remission following high-dose therapy [abstract]. J Clin Oncol. 2010;28:8005.","journal-title":"J Clin Oncol."},{"key":"99_CR29","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1200\/JCO.2008.17.1561","volume":"27","author":"H Hochster","year":"2009","unstructured":"Hochster H, Weller E, Gascoyne RD, et al. Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study. J Clin Oncol. 2009;27:1607\u201314.","journal-title":"J Clin Oncol."},{"key":"99_CR30","doi-asserted-by":"crossref","unstructured":"Salles GA, Seymour JF, Feugier P, et al. Rituximab maintenance for 2\u00a0years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy [abstract]. J Clin Oncol. 2010;28:suppl. abstr 8004.","DOI":"10.1200\/jco.2010.28.15_suppl.8004"},{"key":"99_CR31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0140-6736(10)62175-7","volume":"377","author":"G Salles","year":"2011","unstructured":"\u2022\u2022 Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2\u00a0years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377:42\u201351. This landmark paper confirmed the benefit of rituximab maintenance after first-line treatment of FL, based on a large international trial.","journal-title":"Lancet."},{"key":"99_CR32","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","volume":"101","author":"L Vidal","year":"2009","unstructured":"Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst. 2009;101:248\u201355.","journal-title":"J Natl Cancer Inst."},{"key":"99_CR33","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Vidal L, Gafter-Gvili A, Salles G, et al: Rituximab maintenance for the treatment of patients with follicular lymphoma: Systematic review and meta-analysis of randomized trials-2010 update. 52nd ASH Annual Meeting. Abstract 1798. This update of a systematic review now incorporates data from eight studies and confirms the improved overall survival after rituximab maintenance.","DOI":"10.1182\/blood.V116.21.1798.1798"},{"key":"99_CR34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1056\/NEJMoa041511","volume":"352","author":"MS Kaminski","year":"2005","unstructured":"Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441\u20139.","journal-title":"N Engl J Med."},{"key":"99_CR35","doi-asserted-by":"crossref","unstructured":"Kaminski M, Tuck M, Estes J. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced-stage follicular lymphoma: median 10\u00a0year follow-up results [abstract]. Blood 2009;114:Abstract 3759.","DOI":"10.1182\/blood.V114.22.3759.3759"},{"key":"99_CR36","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s00277-006-0207-0","volume":"86","author":"M Dreyling","year":"2007","unstructured":"Dreyling M, Trumper L, von Schilling C, et al. Results of a national consensus workshop: therapeutic algorithm in patients with follicular lymphoma\u2013role of radioimmunotherapy. Ann Hematol. 2007;86:81\u20137.","journal-title":"Ann Hematol."},{"issue":"Suppl 2","key":"99_CR37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1634\/theoncologist.2009-S2-17","volume":"14","author":"F Morschhauser","year":"2009","unstructured":"Morschhauser F, Dreyling M, Rohatiner A, Hagemeister F, Bischof Delaloye A. Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin\u2019s lymphoma: a review of the evidence. Oncologist. 2009;14 Suppl 2:17\u201329.","journal-title":"Oncologist."},{"issue":"Suppl 2","key":"99_CR38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1634\/theoncologist.2009-S2-4","volume":"14","author":"SA Gregory","year":"2009","unstructured":"Gregory SA, Hohloch K, Gisselbrecht C, Tobinai K, Dreyling M. Harnessing the energy: development of radioimmunotherapy for patients with non-Hodgkin\u2019s lymphoma. Oncologist. 2009;14 Suppl 2:4\u201316.","journal-title":"Oncologist."},{"key":"99_CR39","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3109\/10428194.2011.570396","volume":"52","author":"TE Witzig","year":"2011","unstructured":"\u2022 Witzig TE, Fishkin P, Gordon LI, et al. Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report. Leuk Lymphoma 2011;52:1188\u201399. This updated guideline tells how to incorporate RIT versus implementing rituximab maintenance.","journal-title":"Leuk Lymphoma."},{"key":"99_CR40","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.transci.2011.01.015","volume":"44","author":"MJ Kersten","year":"2011","unstructured":"Kersten MJ. Radioimmunotherapy in follicular lymphoma: some like it hot. Transfus Apher Sci. 2011;44:173\u20138.","journal-title":"Transfus Apher Sci."},{"key":"99_CR41","doi-asserted-by":"crossref","first-page":"4143","DOI":"10.1200\/JCO.2006.05.8198","volume":"24","author":"OW Press","year":"2006","unstructured":"Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab\/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin\u2019s lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143\u20139.","journal-title":"J Clin Oncol."},{"key":"99_CR42","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1200\/JCO.2009.27.8325","volume":"28","author":"BK Link","year":"2010","unstructured":"Link BK, Martin P, Kaminski MS, Goldsmith SJ, Coleman M, Leonard JP. Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study. J Clin Oncol. 2010;28:3035\u201341.","journal-title":"J Clin Oncol."},{"key":"99_CR43","doi-asserted-by":"crossref","first-page":"223","DOI":"10.3816\/CLM.2009.n.044","volume":"9","author":"JD Hainsworth","year":"2009","unstructured":"Hainsworth JD, Spigel DR, Markus TM, et al. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium. Clin Lymphoma Myeloma. 2009;9:223\u20138.","journal-title":"Clin Lymphoma Myeloma."},{"key":"99_CR44","doi-asserted-by":"crossref","first-page":"7088","DOI":"10.1158\/1078-0432.CCR-08-0529","volume":"14","author":"SA Jacobs","year":"2008","unstructured":"Jacobs SA, Swerdlow SH, Kant J, et al. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma. Clin Cancer Res. 2008;14:7088\u201394.","journal-title":"Clin Cancer Res."},{"key":"99_CR45","doi-asserted-by":"crossref","first-page":"8066","DOI":"10.1200\/jco.2010.28.15_suppl.8066","volume":"28","author":"DR Mehta","year":"2010","unstructured":"Mehta DR, Jankowitz R, Lenzer DE, Land SR, Jacobs SA. Phase II study of short course CHOP-rituximab followed by 90Y-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: extended follow-up and predictors of relapse [abstract]. J Clin Oncol. 2010;28:8066.","journal-title":"J Clin Oncol."},{"key":"99_CR46","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1182\/blood.V112.11.3056.3056","volume":"112","author":"P McLaughlin","year":"2008","unstructured":"McLaughlin P, Neelapu S, Fanale M, et al. R-FND followed by radioimmunotherapy for high-risk follicular lymphoma [abstract]. Blood. 2008;112:3056.","journal-title":"Blood."},{"key":"99_CR47","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S1470-2045(08)70039-1","volume":"9","author":"PL Zinzani","year":"2008","unstructured":"Zinzani PL, Tani M, Pulsoni A, et al. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). Lancet Oncol. 2008;9:352\u20138.","journal-title":"Lancet Oncol."},{"key":"99_CR48","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1182\/blood.V114.22.3743.3743","volume":"114","author":"PL Zinzani","year":"2009","unstructured":"Zinzani PL, Tani H, Pulsoni A, et al. A phase II trial of R-FM (rituximab, fludarabine and mitoxantrone) chemotherapy followed by yttrium-90 ibritumomab tiuxetan (90Y-IT) for untreated follicular lymphoma (FL) patients [abstract]. Blood. 2009;114:3743.","journal-title":"Blood."},{"key":"99_CR49","doi-asserted-by":"crossref","first-page":"5156","DOI":"10.1200\/JCO.2008.17.2015","volume":"26","author":"F Morschhauser","year":"2008","unstructured":"\u2022\u2022 Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol. 2008;26:5156\u201364. This randomized trial represents the proof of concept of RIT consolidation in first-line therapy of FL.","journal-title":"J Clin Oncol."},{"key":"99_CR50","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","volume":"25","author":"MS Czuczman","year":"2007","unstructured":"Czuczman MS, Emmanouilides C, Darif M, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;25:4285\u201392.","journal-title":"J Clin Oncol."},{"key":"99_CR51","doi-asserted-by":"crossref","unstructured":"Hagenbeck A, Radford J, Van Hoof A. 90Y-Ibritumomab Tiuxetan (Zevalin\u00ae) Consolidation of First Remission In Advanced-Stage Follicular Non-Hodgkin\u2019s Lymphoma: Updated Results After a Median Follow-up of 66.2 Months From the International, Randomized, Phase III First-Line Indolent Trial (FIT) In 414 Patients [abstract]. Blood 2010;116:Abstract 594.","DOI":"10.1182\/blood.V116.21.594.594"},{"key":"99_CR52","first-page":"544","volume":"3","author":"RI Fisher","year":"2005","unstructured":"Fisher RI. Overview of Southwest Oncology Group clinical trials in non-Hodgkin lymphoma. S0016. A phase III trial of CHOP vs CHOP\u2009+\u2009rituximab vs CHOP\u2009+\u2009iodine131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular NHL. Clin Adv Hematol Oncol. 2005;3:544\u20136.","journal-title":"Clin Adv Hematol Oncol."},{"issue":"5","key":"99_CR53","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3816\/CLM.2006.n.024","volume":"6","author":"BS Kahl","year":"2006","unstructured":"Kahl BS. Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT). Clin Lymphoma Myeloma. 2006;6(5):423\u20136.","journal-title":"Clin Lymphoma Myeloma"},{"key":"99_CR54","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0140-6736(10)62272-6","volume":"377","author":"JW Friedberg","year":"2011","unstructured":"Friedberg JW. Rituximab maintenance in follicular lymphoma: PRIMA. Lancet. 2011;377:4\u20136.","journal-title":"Lancet."},{"key":"99_CR55","doi-asserted-by":"crossref","unstructured":"Ardeshna KM, Qian W, Smith P, Warden J, Stevens L, Pocock CFE, et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a). A preliminary analysis [abstract]. Blood (ASH Annual Meeting Abstracts) 2010;116:Abstract 6.","DOI":"10.1182\/blood.V116.21.6.6"},{"key":"99_CR56","doi-asserted-by":"crossref","unstructured":"Hochster HS, Weller ER, Gascoyne D, Ryan T, Habermann TM, Gordon LI, et al. Cyclophosphamide and fludarabine (CF) in advanced indolent lymphoma: Results from the ECOG\/CALGB intergroup E1496 trial [abstract]. J Clin Oncol 2007; ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement):Abstract 8004.","DOI":"10.1200\/jco.2007.25.18_suppl.8004"},{"issue":"1","key":"99_CR57","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00277-008-0560-2","volume":"88","author":"M Witzens-Harig","year":"2009","unstructured":"Witzens-Harig M, Reiz M, Heiss C, Benner A, Hensel M, Neben K, et al. Quality of life during maintenance therapy with the anti-CD20 antibody rituximab in patients with B cell non-Hodgkin\u2019s lymphoma: results of a prospective randomized controlled trial. Ann Hematol. 2009;88(1):51\u20137.","journal-title":"Ann Hematol."}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-011-0099-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-011-0099-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-011-0099-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T08:50:15Z","timestamp":1592902215000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-011-0099-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,10]]},"references-count":57,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["99"],"URL":"https:\/\/doi.org\/10.1007\/s11899-011-0099-5","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.13366957.14740132","asserted-by":"object"}]},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,10]]}}}